Pharmaceuticals News and Research

RSS

New Calcitonin drug delivery research holds promise for osteoporosis sufferers

Calcitonin, a hormone that lowers calcium levels in the blood and prevents bone loss, has only been available in an injectable and nasally-administered format to date.

1 Jun 2005

La Jolla Pharmaceutical provides update on Riquent

La Jolla Pharmaceutical Company today announced that it has received "fast track" designation for Riquent (abetimus sodium) for the treatment of lupus renal disease from the U.S. Food and Drug Administration (FDA).

31 May 2005

Nastech Pharmaceutical awarded new breast cancer patent

Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psychiatric Disorders."

31 May 2005

Targepeutics issued new U.S patent

Targepeutics has announced the issuance of U.S. Patent No. 6,884,603 for its genetically modified, mutated Interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).

31 May 2005

U.S. pharmaceutical industry is overlooking as much as $16 billion in cash

The pressured U.S. pharmaceutical industry is overlooking as much as $16 billion in cash tied up in excess working capital or the equivalent of up to a full 2.1% of the current total enterprise value, according to the results of a new study by REL Consultancy Group.

31 May 2005

Exposure to pharmaceutical estrogen during fetal development can permanently "reprogram" tissue in a way that determines whether tumors will develop in adulthood

Researchers at The University of Texas M. D. Anderson Cancer Center may have uncovered the reason why some people who are genetically predisposed to hormone-dependent cancers develop the disease as an adult, while others who are similarly susceptible don't.

30 May 2005

Ranbaxy makes further three filings of its Anti-Retroviral (ARVs) formulations

Ranbaxy Laboratories Limited has announced that the Company has made further three filings of its Anti-Retroviral (ARVs) formulations, to the World Health Organization (WHO) for its approval under the latter's pre-qualification project for HIV/AIDS drugs.

30 May 2005

Flavonols in food, key to healthy eating?

University of Melbourne scientists may have found the secret of the fresh fruit and vegetables centred ‘Mediterranean diet’.

29 May 2005

Doubts cast over India's AIDS figures

A controversy has erupted after Indian health workers have, expressed doubts over the new HIV/AIDS figures released by the government, they says the figures are too good to be true.

29 May 2005

Bill Clinton urges U.S. drug companies to be more flexible on generic drugs

Bill Clinton, the former U.S. president, is urging the United States to be more flexible in allowing money pledged for AIDS prevention to be used for low-cost generic drugs, and he has criticized U.S. drug manufacturers for pressuring the government to restrict use of those funds.

26 May 2005

Clinton Foundation aims to treat two million people with HIV in India by 2008

Former United States President Bill Clinton announced in India this week that his Foundation plans to train 150,000 private sector doctors for care and treatment.

26 May 2005

Researchers discover way to reduce plaque deposits on the brain that could slow the progression of Alzheimer's disease

Their findings, which will be highlighted at the upcoming 2005 American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in San Francisco, brings renewed hope to the 4.5 million Americans who have Alzheimer's disease.

26 May 2005

Stimulating innate immunity helps ease Crohn's disease symptoms

Like throwing oil on a fire or prescribing a high cholesterol diet for heart patients, gastroenterologists traditionally have believed that it would not be a good idea to stoke up the body's immune system to treat Crohn's disease.

26 May 2005

Pharmaceutical industry faces multiple challenges - future lies in drug pipeline sustainability

High clinical development costs coupled with declining drug discovery success rates are causing productivity levels to fall in the global pharmaceuticals industry. The imminent patent expiry of several major blockbuster drugs and the related rise of cheaper generic alternatives is further exacerbating the situation.

25 May 2005

NC3Rs announces increased funding for the 3Rs and welcomes the Nuffield Council report

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) announces today that it has been awarded additional money from the Government.

24 May 2005

New cholesterol drug Crestor causes safety concerns

A study by a leading medical journal has concluded that AstraZeneca's controversial drug Crestor produces more than twice as many side effects as other common cholesterol lowering treatments.

24 May 2005

Secrets of how the brain is wired for sex revealed

There are two brain structures that a mouse just can't do without when it comes to hooking up with the mate of its dreams--and trying to stay off the lunch menu of the neighborhood cat. These are the amygdala, which is involved in the initial response to cues that signal love or war, and the hypothalamus, which coordinates the innate reproductive or defensive behaviors triggered by these cues.

23 May 2005

Market forces alone are not sufficient to produce new drugs needed for children with cancer

Faced with "a near absence of research in pediatric cancer drug discovery," the IOM report recommends forming new public-private partnerships among government, industry, researchers, advocacy groups and other parties to lead research and development.

23 May 2005

Discovery may lead to new drugs to treat cancer, control fertility

A recent discovery in cellular biology may allow scientists to enhance organ regeneration by stem cells, prevent the progression of cancer, and control fertility.

22 May 2005

Older adults with insomnia report falling asleep faster with Ramelteon

Results from a Phase 3 clinical study presented at the 2005 Annual Scientific Meeting of the American Geriatrics Society showed that bedtime administration of ramelteon, an investigational compound currently under review for the treatment of insomnia, significantly reduced time to fall asleep in older adults with chronic insomnia. Additionally, no rebound insomnia or withdrawal effects were observed.

18 May 2005